Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 doi-10-17044-scilifelab-26318929-0 https://doi.org/10.17044/SCILIFELAB.26318929 Swedish National Data Service Svensk nationell datatjänst Landing page Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19 doi-10-17044-scilifelab-26318929-0 https://doi.org/10.17044/SCILIFELAB.26318929 Jernbom, August Pin, Elisa Thålin, Charlotte Månberg, Anna 2022-03063_VR Swedish National Data Service Svensk nationell datatjänst Landing page Note: The DOI of the related paper will be provided upon publication. These datasets contain information on autoantibody and anti-SARS-CoV-2 IgG levels. In this study, 478 healthcare workers and 48 patients were followed prospectively over 5 visits from May 2020 to Sept 2021. SARS-CoV-2 serology and autoantibodies were assessed using planar and bead-based arrays. Detected epitopes were validated in blood and cerebrospinal fluid from two independent cohorts of Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29). The datasets contain: - SARS-CoV-2 serological profiles measured in all samples (above) using 3-plex bead arrays. The data is reported as raw and normalized MFI (AU) and compound serostatus. - Proteome-wide autoantibody profiles measured in 12 sample pools using planar arrays. The data is reported as median fluorescent intensity, in raw and normalized arbitrary units (MFI [AU]), and reactivity classification. - Targeted autoantibody profiles measured in 478 healthcare workers and 48 patients across 5 time points using 363-plex bead arrays. The data is reported as raw and normalized MFI (AU), fold change (FC) across infection, and new-onset classification. - Peptide epitope mapping autoantibody profiles measured in a 142 healthcare workers and COVID-19 patients across 2 time points, and all Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29), using 93-plex bead arrays. The data is reported as raw and normalized MFI (AU), and fold change (FC) across infection. Source data is provided with the paper. Access to this individual-level human data can be granted for non-commercial validation purposes and upon reasonable request to the provided contact. A reasonable request should contain the following: - Name of PI and host organization - Contact details - The scientific purpose of the data access request - Commitment to inform when the data has been used in a publication - Commitment not to host or share the data outside the requesting organization - Statement of non-commercial use of data Access to data through an external actor. Åtkomst till data via extern aktör.